Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologic documentation of locally advanced, recurrent or metastatic incurable solid malignancy that has progressed after all available standard therapy or for which standard therapy has proven to be ineffective or intolerable, or is considered inappropriate
Confirmed availability of representative tumor specimens in paraffin blocks/unstained slides
Measurable disease per RECIST v1.1
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Adequate hematologic and end organ function
For female participants of childbearing potential, agreement to use highly effective form(s) of contraception and to continue its use for 6 months after the last dose of MOXR0916
You may not be if
Any anti-cancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment (hormonal therapy with gonadotropin-releasing hormone agonists or antagonists for prostate cancer and palliative radiotherapy greater than (\>) 2 weeks prior to Cycle 1, Day 1 are allowed)
Eligibility based on prior treatment with immunomodulatory agents depends on the mechanistic class of the drug and the cohort for which the participant is being considered
Adverse events from prior anti-cancer therapy that have not resolved to Grade less than or equal to (\</=) 1 except for alopecia or endocrinopathy managed with replacement therapy
Primary central nervous system (CNS) malignancy, or untreated/active CNS metastases
Leptomeningeal disease
Malignancies other than disease under study within 5 years
History of autoimmune disease
History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia, or evidence of active pneumonitis on screening chest computed tomography (CT) scan; history of radiation pneumonitis in the radiation field (fibrosis) is permitted
Positive test for human immunodeficiency virus infection
Active hepatitis B or active hepatitis C
Severe infections within 4 weeks or signs or symptoms of infection within 2 weeks prior to Cycle 1
Prior allogeneic bone marrow transplantation or prior solid organ transplantation
